HIV/AIDS surveillance in the United States, 1981-2001

Journal of Acquired Immune Deficiency Syndromes

Volumn 32, Issue SUPPL. 1, 2003, Pages

  Nakashima, Allyn K ^a   Fleming, Patricia L ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

AIDS; HIV; Surveillance

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DATA ANALYSIS; EVALUATION; HEALTH CARE POLICY; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION PROCESSING; LEGAL ASPECT; PRIORITY JOURNAL; REVIEW; SEROPREVALENCE; TECHNIQUE; UNITED STATES;

EID: 0037321996     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200302011-00011     Document Type: Review

References (106)

1. Centers for Disease Control and Prevention. Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men-New York City and California. MMWR Morb Mortal Wkly Rep 1981; 30:305-8.
2. Center for Disease Control and Prevention. Follow-up on Kaposi's sarcoma and Pneumocystis pneumonia. MMWR Morb Mortal Wkly Rep 1981;30:409-10.
3. Centers for Disease Control and Prevention. Kaposi's sarcoma (KS), Pneumocystis carinii pneumonia (PCP), and other opportunistic infections: cases reported to CDC as of June 15, 1982. Internal reports provided by Surveillance Branch, Division of HIV/AIDS Surveillance, Centers for Disease Control and Prevention.
4. Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a Tlymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868-71.
5. Gallo RC, Salahuddin SZ, Popovic M, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984;224:500-3.
6. Gostin LO, Ward JW, Baker CA. National HIV case reporting for the United States: a defining moment in the history of the epidemic. N Engl J Med 1997;337:1162-7.
7. Bayer R. Private acts, social consequences: AIDS and the politics of public health. New York: Free Press, 1989.
8. Burr C. The AIDS exception: privacy versus public health: The case for reinstating traditional rules for fighting epidemics. Atlantic Monthly 1997(June):57-67.
9. Centers for Disease Control and Prevention. Update: acquired immunodeficiency syndrome B United States. MMWR Morb Mortal Wkly Rep 1985;34:245-8.
10. Centers for Disease Control and Prevention. Update: acquired immunodeficiency syndrome-United States. MMWR Morb Mortal Wkly Rep 1986;35:17-21.
11. Matthews GW, Churchill RE. Public health surveillance and the law. In: Teutsch SM, Churchill RE, eds. Principles and practice of public health surveillance. New York: Oxford University Press, 1994:190-9.
12. Public Health Service Act (42 USC 242k and 242m[d]) Sections 306 and 308(d).
13. Gostin LO. Public health strategies for confronting AIDS: legislative and regulatory policy in the United States. JAMA 1989; 261:1621-30.
14. Gostin LO, Lazzarini Z, Neslund VS, ET AL. The public health information infrastructure: a national review of the law on health information privacy. JAMA 1996;275:1921-7.
15. Gostin LO, Webber DW. The AIDS Litigation Project: HIV/AIDS in the courts in the 1990s, part 1. AIDS & Public Policy J 1997; 12:105-21.
16. Gostin LO, Webber DW. The AIDS Litigation Project: HIV/AIDS in the courts in the 1990s, part 2. AIDS & Public Policy J 1998; 13:3-19.
17. Landry S. AIDS list is out: state investigating breach. St. Petersburg, Florida: St. Petersburg Times, September 20, 1996:51.
18. Fleming PL, Gwinn M. Human immunodeficiency virus. In: Wilcox LS, Marks JS, eds. From data to action: CDC's public health surveillance for women, infants, and children. Atlanta, Ga: Centers for Disease Control and Prevention, 1994:49-61.
19. Centers for Disease Control and Prevention. Guidelines for HIV/AIDS surveillance. Atlanta, Ga: Centers for Disease Control and Prevention, 1996.
20. Centers for Disease Control and Prevention. HIV/AIDS surveillance: confidentiality and security policies and procedures. Atlanta, Ga: Centers for Disease Control and Prevention, 1996.
21. Centers for Disease Control and Prevention. Update on acquired immune deficiency syndrome (AIDS)-United States. MMWR Morb Mortal Wkly Rep 1982;31:507-14.
22. Centers for Disease Control and Prevention. Revision of the case definition of acquired immunodeficiency syndrome for national reporting-United States. MMWR Morb Mortal Wkly Rep 1985; 34:373-5.
23. Centers for Disease Control and Prevention. Classification system for T-lymphotropic virus type III/lymphadenopathy virus infections. MMWR Morb Mortal Wkly Rep 1986;35:334-9.
24. Centers for Disease Control and Prevention. Classification system for human immunodeficiency virus (HIV) infection in children under 13 years of age. MMWR Morb Mortal Wkly Rep 1987;36: 225-30, 235.
25. Centers for Disease Control and Prevention. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep 1987; 36(1S):1S-15S.
26. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1993;41(RR-17):1-19.
27. Centers for Disease Control and Prevention. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Morb Mortal Wkly Rep 1994;43(RR-12):1-10.
28. Hardy AM, Starcher ET, Morgan WM, et al. Review of death certificates to assess completeness of reporting. Public Health Rep 1987;102:386-91.
29. Buehler JW, Berkelman RL, Stehr-Green JK. The completeness of AIDS surveillance. J Acquir Immune Def Syndr 1992;5: 257-64.
30. Rosenblum L, Buehler JW, Morgan MW, et al. The completeness of AIDS case reporting, 1988: a multisite collaborative surveillance project. Am J Public Health 1992;82:1495-9.
31. Centers for Disease Control and Prevention. Surveillance of tuberculosis and AIDS co-morbidity. MMWR Morb Mortal Wkly Rep 1996;45:38-40.
32. Greenberg AE, Hindlin R, Nicholas AG, Bryan E, Thomas PA. The completeness of AIDS case reporting in New York City. JAMA 1993;269:2995-3001.
33. Centers for Disease Control and Prevention. Assessment of laboratory reporting to supplement active AIDS surveillance-Colorado. MMWR Morb Mortal Wkly Rep 1996;45:749-52.
34. Klevens RM, Fleming PL, Li J, Karon JM. Impact of laboratoryinitiated reporting of CD4+ T lymphocytes on U.S. AIDS surveillance. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:56-60.
35. Jones JL, Hanson DL, Chu SY, et al. Surveillance of AIDS-defining conditions in the United States. AIDS 1994;8:1489-93.
36. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2001;13(No. 2):1-44.
37. Karon JM, Devine OJ, Morgan WM. Predicting AIDS incidence by extrapolating from recent trends. In: Castillo-Chevez C, ed. Mathematical and statistical approaches to AIDS epidemiology: lecture notes in biomathematics. New York: Springer Verlag NY Inc: 1989:58-88.
38. Nwanyanwu OC, Conti LA, Ciesielski CA, et al. Increasing frequency of heterosexually transmitted AIDS in Southern Florida: artifact or reality? Am J Public Health 1993;83:571-3.
39. Klevens RM, Fleming PL, Neal JJ, Li J, and the Mode of Transmission Study Group. Is there really a heterosexual AIDS epidemic in the United States? Findings from a multisite validation study, 1992-1995. Am J Epidemiol 1999;149:75-84.
40. Castro KG, Lifson AR, White CR, et al. Investigations of AIDS patients with no previously identified risk factors. JAMA 1988; 259:1338-42.
41. Hammett TA, Ciesielski CA, Bush TJ, Fleming PL, Ward JW. Impact of the 1993 expanded AIDS case definition on reporting of persons without HIV risk information. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:259-62.
42. Green TA, Karon JM, Nwanyanwu OC. Changes in AIDS incidence trends in the United States. J Acquir Immune Defic Syndr Hum Retrovirol 1992;5:547-55.
43. Neal JJ, Fleming PL, Green TA, et al. Trends in heterosexually acquired AIDS in the United States, 1988 through 1995. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:465-74.
44. Selik RM, Buehler JW, Karon JM, Chamberland ME, Berkelman RL. Impact of the 1987 revision of the case definition of the acquired immune deficiency syndrome in the United States. J Acquir Immune Defic Syndr Hum Retrovirol 1990;3:73-82.
45. Centers for Disease Control and Prevention. Update: impact of the expanded AIDS surveillance case definition for adolescents and adults on case reporting-United States, 1993. MMWR Morb Mortal Wkly Rep 1994;43:160-1,167-70.
46. Karon JM, Green TA, Hanson DL, et al. Estimating the number of persons diagnosed with AIDS-defining opportunistic illnesses from data collected under the 1993 AIDS surveillance definition. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:116-21.
47. Green TA. Using surveillance data to monitor trends in the AIDS epidemic. Stat Med 1998;17:143-54.
48. Farizo KM, Buehler JW, Chamberland ME, et al. Spectrum of disease in persons with human immunodeficiency virus infection in the United States. JAMA 1992;267:1798-1805.
49. Simonds RJ, Lindegren ML, Thomas P, et al. Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. N Engl J Med 1995;332:786-90.
50. Buehler JM, Diaz T, Hersh BS, Chu SY. The Supplement to HIV-AIDS Surveillance project: an approach for monitoring HIV risk behaviors. Public Health Rep 1996;111(suppl 1):133-7.
51. Kelly JJ, Vhu SY, Diaz T, et al. Race/ethnicity misclassification of persons reported with AIDS. Ethn Health 1996;1:87-94.
52. Jones JL, Hanson DL, Dworkin MS, et al. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997. MMWR Morb Mortal Wkly Rep 1999;48(SS-2):1-22.
53. Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States. JAMA 1999; 281:2305-15.
54. Fleming PL, Ward JW, Karon JM, Hanson DL, DeCock KM. Declines in AIDS incidence and deaths in the USA: a signal change in the epidemic. AIDS 1998;12(suppl A):S55-S61.
55. Rosenberg PS. Scope of the AIDS epidemic in the United States. Science 1995;270:1372-5.
56. Lemp GF, Porco TC, Hirozawa AM, et al. Projected incidence of AIDS in San Francisco: the peak and decline of the epidemic. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:182-9.
57. Karon JM, Fleming PL, Steketee RW, et al. HIV in the United States at the turn of the century: an epidemic in transition. Am J Publ Health 2001;91:1060-8.
58. Centers for Disease Control and Prevention. HIV/AIDS among men of color who have sex with men-United States, January 1986-December 1998. MMWR Morb Mortal Wkly Rep 2000;49: 4-11.
59. Wortley PM, Fleming PL. AIDS in women in the United States: recent trends. JAMA 1997;278:911-6.
60. Centers for Disease Control and Prevention. AIDS associated with injecting-drug use-United States, 1995. MMWR Morb Mortal Wkly Rep 1996;45:392-8.
61. Lindegren ML, Byers RH, Thomas P, et al. Trends in perinatal transmission of HIV/AIDS in the United States. JAMA 1999;282: 531-8.
62. Neal JJ, McNaghten AD, Council of State and Territorial Epidemiologists. Trends in the use of epidemiologic data in HIV prevention community planning in the United States, 1994 through 1997 [abstract 43501]. Program and abstracts of the XII International Conference on AIDS, Geneva, Switzerland, 1998.
63. Forbes A. Naming names-mandatory name-based HIV reporting: impact and alternatives. AIDS Policy & Law 1996(May): 1-4.
64. Should HIV test results be reportable? A discussion of the key policy questions. Washington, DC: AIDS Action Foundation; 1993.
65. Fordyce JE, Sambula S, Stoneburner R. Mandatory reporting of human immunodeficiency virus testing would deter blacks and Hispanics from being tested [letter]. JAMA 1989;262:349.
66. Kegeles SM, Catania JA, Coates TJ, et al. Many people who seek anonymous HIV-antibody testing would avoid it under other circumstances. AIDS 1990;4:585-7.
67. Myers T, Orr KW, Locker D, et al. Factors affecting gay and bisexual men's decisions and intentions to seek HIV testing. Am J Public Health 1993;83:701-4.
68. American Civil Liberties Union. HIV surveillance and name reporting: a public health case for protecting civil liberties. Washington, DC: American Civil Liberties Union, October 1997.
69. Burris S. Driving the epidemic underground? A new look at law and the social risk of HIV testing. AIDS & Public Policy Journal 1997;12:66-78.
70. Centers for Disease Control and Prevention. Evaluation of HIV case surveillance through the use of non-name unique identifiers-Maryland and Texas, 1994-1996. MMWR Morb Mortal Wkly Rep 1998;46:1254-8,1271.
71. Centers for Disease Control and Prevention. Integrating HIV and AIDS surveillance: a resource manual for surveillance coordinators. Atlanta, Ga: Centers for Disease Control and Prevention, 1998.
72. Gostin LO, Hodge JG. Model state public health privacy act. Washington, DC: Georgetown University Law Center, August 1999.
73. Fullem A, Knowlton R, Verma B, et al. A non-name-based system for HIV surveillance in Massachusetts [abstract 423]. Program and abstracts of the 1st National HIV Prevention Conference, Atlanta, Georgia, 1999.
74. Robbins A, Hamaker D, Thomas M, et al. HIV reporting by unique identifier: the Texas experience [abstract 594]. Program and abstracts of the 1st National HIV Prevention Conference, Atlanta, Georgia, 1999.
75. Centers for Disease Control and Prevention. Guidelines for national human immunodeficiency virus case surveillance, including monitoring for human immunodeficiency virus infection and acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep 1999;48(RR-13):1-31.
76. Nakashima AK, Horsley RM, Frey RL, et al. Effect of HIV reporting by name on use of HIV testing in publicly funded counseling and testing sites. JAMA 1998;280:1421-6.
77. Centers for Disease Control and Prevention. HIV testing among populations at risk for HIV infection-nine states. MMWR Morb Mortal Wkly Rep 1998;47:1086-91.
78. Marsh K, Morgan M, Bunch G, et al. Evaluation of non-namecoded identifiers in Los Angeles County and New Jersey [abstract 459]. Program and abstracts of the 1st National HIV Prevention Conference, Atlanta, Georgia, 1999.
79. Centers for Disease Control and Prevention. Estimates of HIV prevalence and projected AIDS cases: a summary of a workshop, October 31 -November 1, 1989. MMWR Morb Mortal Wkly Rep 1990;39:110-2;117-9.
80. Rosenberg PS. Scope of the AIDS epidemic in the United States. Science 1995;270:1372-5.
81. Karon JM, Rosenberg PS, McQuillan G, et al. Prevalence of HIV infection in the United States, 1984-1992. JAMA 1996;276:126-31.
82. Fleming PL, Byers RH, Sweeney PA, Daniels D, Karon JM, Janssen RS. HIV prevalence in the United States 2000. Presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, February 24-28, 2002. [Abstract No. 11]
83. Karon JM, Khare M, Rosenberg R. The current status of methods for estimating prevalence of human immunodeficiency virus in the United States of America. Stat Med 1998;17:127-42.
84. Holtzman D, Bland SD, Nakashima A. HIV testing rates and trends among U.S. adults, 1994-1997 [abstract 470]. Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, 1999.
85. Centers for Disease Control and Prevention. National HIV prevalence surveys, 1997 summary. Atlanta, Ga: Centers for Disease Control and Prevention, 1998:1-25.
86. Pappaioanou M, Goerge J, Hannon W, et al. HIV seroprevalence surveys of childbearing women: objectives, methods, and uses of the data. Public Health Rep 1990;105:147-52.
87. Davis SF, Rosen DH, Steinberg S, et al. Trends in HIV prevalence among childbearing women in the United States, 1989-1994. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19: 158-64.
88. McCray E, Onorato IM. Sentinel surveillance of human immunodeficiency virus infection in sexually transmitted disease clinics in the United States. Sex Transm Dis 1992;19:235-41.
89. Weinstock HS, Sidhu J, Gwinn M, et al. Trends in HIV seroprevalence among persons attending sexually transmitted disease clinics in the United States, 1988-1992. J Acquir Immune Defic Syndr Hum Retrovirol 1995;9:514-22.
90. Allen DM, Onorato IM, Green TA. HIV infection in intravenous drug users entering drug treatment, United States, 1988 to 1989. Am J Public Health 1992;82:541-6.
91. Prevots DR, Allen DM, Lehman JS, et al. Trends in human immunodeficiency virus seroprevalence among injecting drug users entering drug treatment centers, United States, 1988-93. Am J Epidemiol 1996;143:733-42.
92. Lindegren ML, Hansen C, Miller K, et al. Epidemiology of human immunodeficiency virus in adolescents, Untied States. Pediatr Infect Dis J 1994;13:525-35.
93. Sweeney P, Lindegren ML, Buehler JW, et al. Teenagers at risk for human immunodeficiency virus type 1 infection. Arch Pediatr Adolesc Med 1995;149:521-8.
94. Valleroy LA, MacKellar DA, Karon JM, et al. HIV infection in disadvantaged out-of-school youth: prevalence for U.S. Job Corps entrants 1990 through 1996. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:67-73.
95. Brundage JF, Burke DS, Gardner LI, et al. Tracking the spread of the HIV infection epidemic among young adults in the U.S.: results of the first four years of screening among civilian applicants for military service. J Acquir Immune Defic Syndr 1990;3: 1168-80.
96. Lackritz EM, Satten GA, Aberle-Grasse J, et al. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med 1995;333:1721-5.
97. Weinstock H, Sweeney S, Satten GA, et al. HIV seroincidence and risk factors among patients repeatedly tested for HIV attending sexually transmitted disease clinics in the United States, 1991 to 1996. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19: 506-12.
98. Des Jarlais DC, Marmor M, Friedmann P, et al. HIV incidence among injection drug users in New York City, 1992-1997: evidence for a declining epidemic. Am J Public Health 2000;90: 352-9.
99. Janssen RS, Satten GA, Stramer SL, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA 1998;280:42-8.
100. Valleroy L, MacKellar DA, Rosen D, et al. HIV and predictors of unprotected receptive anal intercourse for 15- to 22-year-old African-American men who have sex with men in seven cities, USA [abstract 23120]. Program and abstracts of the XII International Conference on AIDS, Geneva, Switzerland, 1998.
101. Centers for Disease Control and Prevention. HIV counseling and testing in publicly funded sites: 1996 annual report. Atlanta, Ga.: Centers for Disease Control and Prevention, 1998.
102. Powell-Griner E, Anderson JE, Murphy W. State- and sex-specific prevalence of selected characteristics-Behavioral Risk Factor Surveillance System, 1994 and 1995. MMWR Morb Moral Wkly Rep 1997;46(SS-3):1-29.
103. Centers for Disease Control and Prevention. HIV testing-United States, 1996. MMWR Morb Mortal Wkly Rep 1999;48:52-5.
104. Safran MA, Wilson RW. Surveillance of HIV knowledge, attitudes and beliefs, and behaviors in the general population. Public Health Rep 1996;111(suppl 1):123-8.
105. Anderson JE, Wilson RW, Barker P, et al. Prevalence of sexual and drug-related HIV risk behaviors in the U.S. adult population: results of the 1996 national household survey on drug abuse. J Acquir Immune Defic Syndr 1999;21:148-56.
106. Centers for Disease Control and Prevention. Trends in HIV-related sexual risk behaviors among high school students-selected U.S. cities, 1991-1997. MMWR Morb Mortal Wkly Rep 1999;48:440-3.